Indivior Pharmaceuticals (INDV) Net Income towards Common Stockholders (2024 - 2026)

Indivior Pharmaceuticals' Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at $89.0 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 85.42% year-over-year to $89.0 million in Q1 2026; TTM through Mar 2026 was $251.0 million, a 3685.71% increase from a year earlier, with the FY2025 full-year figure at $210.0 million, up 2900.0% from the prior year.
• Net Income towards Common Stockholders declined to $89.0 million in Q1 2026 per INDV's latest filing, from $102.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $102.0 million in Q4 2025 and bottomed at -$98.0 million in Q2 2024.
• The 3-year median for Net Income towards Common Stockholders is $42.0 million (2025), against an average of $34.0 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 385.71% in 2025; the steepest drop was 22.58% in 2025.
• Year by year, Net Income towards Common Stockholders stood at $21.0 million in 2024, then soared by 385.71% to $102.0 million in 2025, then slipped by 12.75% to $89.0 million in 2026.
• Per Business Quant, the three latest INDV Net Income towards Common Stockholders figures stand at $89.0 million (Q1 2026), $102.0 million (Q4 2025), and $42.0 million (Q3 2025).